Infiltrating leukocytes surround early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria

References

• WHO | Laboratory diagnosis of buruli ulcer [Internet]. WHO [cited 2014 Jul 16]; Available from: http://www.who.int/buruli/laboratory_diagnosis/en/
   Google Scholar
• Junghanss T, Johnson C, Pluschke G. Mycobacterium ulcerans disease. In: Manson's tropical diseases. Edinburgh: Saunders Ltd; 2014. p. 519-31.
   Google Scholar
• Pluschke G, Röltgen K. Epidemiology and disease burden of Buruli ulcer: A review. Res Rep Trop Med. 2015;6:59-73. doi:https://doi.org/10.2147/RRTM.S62026
   Google Scholar
• Steffen CM, Smith M, McBride WJH. Mycobacterium ulcerans infection in North Queensland: the “Daintree ulcer.” ANZ J Surg. 2010;80:732-6. doi:https://doi.org/10.1111/j.1445-2197.2010.05338.x. PMID:21040335
   PubMed Web of Science ®Google Scholar
• Steffen CM, Freeborn H. Mycobacterium ulcerans in the Daintree 2009–2015 and the mini-epidemic of 2011. ANZ J Surg. 2016; PMID:27804194
   PubMed Web of Science ®Google Scholar
• Flood P, Street A, O'Brien P, Hayman J. Mycobacterium ulcerans infection on Phillip Island, Victoria. Med J Aust. 1994;160:160. PMID:8295586
   PubMed Web of Science ®Google Scholar
• Hayman JA, Huygens HJ. Mycobacterium ulcerans infection across Lake Victoria. Med J Aust. 1982;1:138. PMID:7132854
   PubMed Web of Science ®Google Scholar
• Hayman J. Mycobacterium ulcerans infection in Victoria: celebration of a golden jubilee? Australas J Dermatol. 1987;28:99-105. doi:https://doi.org/10.1111/j.1440-0960.1987.tb00346.x. PMID:3504150
   PubMedGoogle Scholar
• Johnson PDR, Lavender CJ. Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerging Infect Dis. 2009;15:614-5. doi:https://doi.org/10.3201/eid1504.081162. PMID:19331750
   PubMedGoogle Scholar
• van Ravensway J, Benbow ME, Tsonis AA, Pierce SJ, Campbell LP, Fyfe JAM, Hayman JA, Johnson PDR, Wallace JR, Qi J. Climate and landscape factors associated with Buruli ulcer incidence in Victoria, Australia. PLoS ONE. 2012;7:e51074. doi:https://doi.org/10.1371/journal.pone.0051074. PMID:23251425
   PubMedGoogle Scholar
• Boyd SC, Athan E, Friedman ND, Hughes A, Walton A, Callan P, McDonald A, O'Brien DP. Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. Med J Aust. 2012;196:341-4. doi:https://doi.org/10.5694/mja12.10087. PMID:22432674
   PubMed Web of Science ®Google Scholar
• George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, Small PL. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science. 1999;283:854-7. doi:https://doi.org/10.1126/science.283.5403.854. PMID:9933171
   PubMed Web of Science ®Google Scholar
• Bieri R, Scherr N, Ruf M-T, Dangy J-P, Gersbach P, Gehringer M, Altmann K-H, Pluschke G. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chem Biol. 2017;12:1297-1307. doi:https://doi.org/10.1021/acschembio.7b00053. PMID:28294596.
   PubMedGoogle Scholar
• Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, Small PLC. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol. 2005;7:1295-304. doi:https://doi.org/10.1111/j.1462-5822.2005.00557.x. PMID:16098217
   PubMed Web of Science ®Google Scholar
• Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, Tanguy M, Cole ST, Small PLC, Demangel C. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol. 2005;7:1187-96. doi:https://doi.org/10.1111/j.1462-5822.2005.00546.x. PMID:16008585
   PubMed Web of Science ®Google Scholar
• Simmonds RE, Lali FV, Smallie T, Small PLC, Foxwell BM. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol. 2009;182:2194-202. doi:https://doi.org/10.4049/jimmunol.0802294. PMID:19201873
   PubMed Web of Science ®Google Scholar
• Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, Foxwell BM. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol. 1999;163:3928-35. PMID:10490994
   PubMed Web of Science ®Google Scholar
• Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, Albert ML, Demangel C. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med. 2007;204:1395-403. doi:https://doi.org/10.1084/jem.20070234. PMID:17517970
   PubMed Web of Science ®Google Scholar
• Boulkroun S, Guenin-Macé L, Thoulouze M-I, Monot M, Merckx A, Langsley G, Bismuth G, Di Bartolo V, Demangel C. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol. 2010;184:1436-44. doi:https://doi.org/10.4049/jimmunol.0902854. PMID:20042571
   PubMed Web of Science ®Google Scholar
• Torrado E, Adusumilli S, Fraga AG, Small PLC, Castro AG, Pedrosa J. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun. 2007;75:3979-88. doi:https://doi.org/10.1128/IAI.00290-07. PMID:17517872
   PubMed Web of Science ®Google Scholar
• Guenin-Macé L, Carrette F, Asperti-Boursin F, Le Bon A, Caleechurn L, Di Bartolo V, Fontanet A, Bismuth G, Demangel C. Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci USA. 2011;108:12833-8. doi:https://doi.org/10.1073/pnas.1016496108. PMID:21768364
   PubMed Web of Science ®Google Scholar
• Asiedu K, Scherpbier, R, Raviglione, M. Buruli ulcer: Mycobacterium ulcerans infection. Geneva: World Health Organization. 2000.
   Google Scholar
• van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet. 1999;354:1013-8. doi:https://doi.org/10.1016/S0140-6736(99)01156-3. PMID:10501380
   PubMed Web of Science ®Google Scholar
• Hayman J. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J Clin Pathol. 1993;46:5-9. doi:https://doi.org/10.1136/jcp.46.1.5. PMID:8432888
   PubMed Web of Science ®Google Scholar
• Hayman J, McQueen A. The pathology of Mycobacterium ulcerans infection. Pathology. 1985;17:594-600. doi:https://doi.org/10.3109/00313028509084759. PMID:4094789
   PubMed Web of Science ®Google Scholar
• Stienstra Y, van der Graaf WTA, Asamoa K, van der Werf TS. Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg. 2002;67:207-13. doi:https://doi.org/10.4269/ajtmh.2002.67.207. PMID:12389949
   PubMed Web of Science ®Google Scholar
• O'Brien DP, Friedman ND, Cowan R, Pollard J, McDonald A, Callan P, Hughes A, Athan E. Mycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal Outcomes. PLoS Negl Trop Dis. 2015;9:e0004253. doi:https://doi.org/10.1371/journal.pntd.0004253. PMID:26630648
   PubMed Web of Science ®Google Scholar
• WHO | Treatment of Mycobacterium ulcerans disease (Buruli Ulcer) [Internet]. WHO [cited 2016 Apr 29]; Available from: http://www.who.int/buruli/treatment/en/.
   Google Scholar
• O'Brien DP, Jenkin G, Buntine J, Steffen CM, McDonald A, Horne S, Friedman ND, Athan E, Hughes A, Callan PP, et al. Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Med J Aust. 2014;200:267-70. doi:https://doi.org/10.5694/mja13.11331. PMID:24641151
   PubMed Web of Science ®Google Scholar
• Friedman ND, Athan E, Hughes AJ, Khajehnoori M, McDonald A, Callan P, Rahdon R, O'Brien DP. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLoS Negl Trop Dis. 2013;7:e2315. doi:https://doi.org/10.1371/journal.pntd.0002315. PMID:23875050
   PubMed Web of Science ®Google Scholar
• Friedman ND, Athan E, Walton AL, O'Brien DP. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. Antimicrob Agents Chemother. 2016;60:2692-5. doi:https://doi.org/10.1128/AAC.02853-15. PMID:26883709
   PubMed Web of Science ®Google Scholar
• Bratschi MW, Bolz M, Minyem JC, Grize L, Wantong FG, Kerber S, Njih Tabah E, Ruf M-T, Mou F, Noumen D, et al. Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon. PLoS Negl Trop Dis. 2013;7:e2252. doi:https://doi.org/10.1371/journal.pntd.0002252. PMID:23785529
   PubMed Web of Science ®Google Scholar
• Capela C, Sopoh GE, Houezo JG, Fiodessihoué R, Dossou AD, Costa P, Fraga AG, Menino JF, Silva-Gomes R, Ouendo EM, et al. Clinical Epidemiology of Buruli Ulcer from Benin (2005-2013): Effect of Time-Delay to Diagnosis on Clinical Forms and Severe Phenotypes. PLoS Negl Trop Dis. 2015;9:e0004005. doi:https://doi.org/10.1371/journal.pntd.0004005. PMID:26355838
   PubMed Web of Science ®Google Scholar
• Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Scott JT, Dramaix M, Portaels F. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health. 2004;9:1297-304. doi:https://doi.org/10.1111/j.1365-3156.2004.01339.x. PMID:15598261
   PubMed Web of Science ®Google Scholar
• Ruf M-T, Sopoh GE, Brun LV, Dossou AD, Barogui YT, Johnson RC, Pluschke G. Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue? PLoS Negl Trop Dis. 2011;5:e1334. doi:https://doi.org/10.1371/journal.pntd.0001334. PMID:21980547
   PubMed Web of Science ®Google Scholar
• Bolz M, Ruggli N, Borel N, Pluschke G, Ruf M-T. Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model. PLoS Negl Trop Dis. 2016;10:e0004678. doi:https://doi.org/10.1371/journal.pntd.0004678. PMID:27128097
   PubMed Web of Science ®Google Scholar
• Bolz M, Ruggli N, Ruf M-T, Ricklin ME, Zimmer G, Pluschke G. Experimental infection of the pig with Mycobacterium ulcerans: A novel model for studying the pathogenesis of Buruli ulcer disease. PLoS Negl Trop Dis. 2014;8:e2968. doi:https://doi.org/10.1371/journal.pntd.0002968. PMID:25010421
   PubMed Web of Science ®Google Scholar
• Diaz D, Dobeli H, Yeboah-Manu D, Mensah-Quainoo E, Friedlein A, Soder N, Rondini S, Bodmer T, Pluschke G. Use of the Immunodominant 18-Kilodalton Small Heat Shock Protein as a Serological Marker for Exposure to Mycobacterium ulcerans. Clin Vaccine Immunol. 2006;13:1314-21. doi:https://doi.org/10.1128/CVI.00254-06. PMID:17021247
   PubMed Web of Science ®Google Scholar
• Ampah KA, Nickel B, Asare P, Ross A, De-Graft D, Kerber S, Spallek R, Singh M, Pluschke G, Yeboah-Manu D, et al. A Sero-epidemiological Approach to Explore Transmission of Mycobacterium ulcerans. PLoS Negl Trop Dis. 2016;10:e0004387. doi:https://doi.org/10.1371/journal.pntd.0004387. PMID:26808978
   PubMedGoogle Scholar
• Röltgen K, Bratschi MW, Ross A, Aboagye SY, Ampah KA, Bolz M, Andreoli A, Pritchard J, Minyem JC, Noumen D, et al. Late onset of the serological response against the 18 kDa small heat shock protein of Mycobacterium ulcerans in children. PLoS Negl Trop Dis. 2014;8:e2904. doi:https://doi.org/10.1371/journal.pntd.0002904. PMID:24853088
   PubMedGoogle Scholar
• Schütte D, Umboock A, Pluschke G. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J Dermatol. 2009;160:273-83. doi:https://doi.org/10.1111/j.1365-2133.2008.08879.x. PMID:19016694
   PubMed Web of Science ®Google Scholar
• Ruf M-T, Chauty A, Adeye A, Ardant M-F, Koussemou H, Johnson RC, Pluschke G. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis. 2011;5:e1252. doi:https://doi.org/10.1371/journal.pntd.0001252. PMID:21829740
   PubMed Web of Science ®Google Scholar
• Ruf M-T, Schütte D, Chauffour A, Jarlier V, Ji B, Pluschke G. Chemotherapy associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model. Antimicrob Agents Chemother. 2012;56:687-96. doi:https://doi.org/10.1128/AAC.05543-11
   Google Scholar
• Marsollier L, Brodin P, Jackson M, Korduláková J, Tafelmeyer P, Carbonnelle E, Aubry J, Milon G, Legras P, André J-PS, et al. Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog. 2007;3:e62. doi:https://doi.org/10.1371/journal.ppat.0030062. PMID:17480118
   PubMed Web of Science ®Google Scholar
• Merritt RW, Walker ED, Small PLC, Wallace JR, Johnson PDR, Benbow ME, Boakye DA. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis. 2010;4:e911. doi:https://doi.org/10.1371/journal.pntd.0000911. PMID:21179505
   PubMed Web of Science ®Google Scholar
• Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, Portaels F, Silva MT, Pedrosa J. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun. 2007;75:977-87. doi:https://doi.org/10.1128/IAI.00889-06. PMID:17145944
   PubMed Web of Science ®Google Scholar
• Ruf M-T, Bolz M, Vogel M, Bayi PF, Bratschi MW, Sopho GE, Yeboah-Manu D, Um Boock A, Junghanss T, Pluschke G. Spatial Distribution of Mycobacterium ulcerans in Buruli Ulcer Lesions: Implications for Laboratory Diagnosis. PLoS Negl Trop Dis. 2016;10:e0004767. doi:https://doi.org/10.1371/journal.pntd.0004767. PMID:27253422
   PubMed Web of Science ®Google Scholar
• Scherr N, Gersbach P, Dangy J-P, Bomio C, Li J, Altmann K-H, Pluschke G. Structure-activity relationship studies on the macrolide exotoxin mycolactone of Mycobacterium ulcerans. PLoS Negl Trop Dis. 2013;7:e2143. doi:https://doi.org/10.1371/journal.pntd.0002143. PMID:23556027
   PubMedGoogle Scholar
• Mve-Obiang A, Lee RE, Portaels F, Small PLC. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun. 2003;71:774-83. doi:https://doi.org/10.1128/IAI.71.2.774-783.2003. PMID:12540557
   PubMed Web of Science ®Google Scholar